Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461030 | 0.96 | APP (0.32) | S1PR1S1PR5APP | |
| SCHEMBL2513007 | 0.95 | S1PR1 (0.34) | S1PR1S1PR5APPPTGS2 | |
| SCHEMBL4479930 | 0.94 | CYP3A4 (0.33) | S1PR1S1PR5 | |
| SCHEMBL1023781 | 0.92 | S1PR1 (0.32) | S1PR1S1PR5 | |
| SCHEMBL5951608 | 0.92 | S1PR1 (0.38) | S1PR1S1PR5APPPTGS2 | |
| SCHEMBL4464839 | 0.92 | — | — | |
| SCHEMBL4463039 | 0.91 | S1PR1 (0.32) | S1PR1S1PR5 | |
| SCHEMBL1024288 | 0.90 | S1PR1 (0.33) | S1PR1S1PR5APP | |
| SCHEMBL1024441 | 0.90 | S1PR1 (0.33) | S1PR1S1PR5APP | |
| SCHEMBL4465418 | 0.89 | APP (0.30) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034886-B2 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100056737-A1 | Process for manufacturing high to ultra high molecular weight polymers using novel bridged metallocene catalysts | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2010-03-04 | — | — | US | disclosed |
| US-7598329-B2 | Process for manufacturing ultra high molecular weight polymers using novel bridged metallocene catalysts | TICONA GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7569651-B2 | Transition metal compound, ligand system, catalyst system and its use for the polymerization and copolymerization of olefins | BASELL POLYPROPYLEN GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-7342078-B2 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | BASELL POLYOLEFINE GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-20070105712-A1 | Process for manufacturing ultra high molecular weight polymers using novel bridged metallocene catalysts | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20060020096-A1 | Transition metal compound, ligand system, catalyst system and its use for the polymerization and copolymerization of olefins | SCHOTTEK JORG | 2006-01-26 | — | — | US | disclosed |
| US-20030149199-A1 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | BASELL POLYPROPYLEN GMBH (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149199-A1 | Transition metal compound, ligand system, catalyst system and the use of the latter for polymerisation and copolymerisation of olefins | PORCN, PGR, PPOX | S1PR1 3967/4885S1PR5 4420/4885APP 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.